Ebalzotan
Ebalzotan (NAE-086) is a selective 5-HT1A receptor agonist.[1][2] It was under development as an antidepressant and anxiolytic agent but produced undesirable side effects in phase I clinical trials and was subsequently discontinued.[1][2]
 | |
| Clinical data | |
|---|---|
| Routes of administration | Oral |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C19H30N2O2 |
| Molar mass | 318.45 g/mol g·mol−1 |
| 3D model (JSmol) | |
SMILES
| |
See also
References
- Tamim Braish; Gadamasetti, Kumar G. (2008). Process chemistry in the pharmaceutical industry, volume 2 challenges in an ever changing climate. Boca Raton: CRC Press. ISBN 0-8493-9051-6.
- Weaver, Donald F.; Nogrady, Thomas; Nogrady, Th (2005). Medicinal chemistry a molecular and biochemical approach. Oxford [Oxfordshire]: Oxford University Press. ISBN 0-19-510455-2.
| 5-HT1AR agonists | |
|---|---|
| GABAAR PAMs |
|
| Gabapentinoids (α2δ VDCC blockers) | |
| Antidepressants |
|
| Sympatholytics (Antiadrenergics) |
|
| Others | |
| |
Serotonin receptor modulators | |||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 5-HT1 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT2 |
| ||||||||||||||||||||||||||||||||||||||
| 5-HT3–7 |
| ||||||||||||||||||||||||||||||||||||||
| |||||||||||||||||||||||||||||||||||||||
This article is issued from
Wikipedia.
The text is licensed under Creative
Commons - Attribution - Sharealike.
Additional terms may apply for the media files.